Zealand Pharma A/S (ZLDPF)
47.64
0.00 (0.00%)
USD |
OTCM |
Sep 04, 16:00
Zealand Pharma Research and Development Expense (Quarterly) : 80.28M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 80.28M |
| March 31, 2026 | 73.45M |
| December 31, 2025 | 82.61M |
| September 30, 2025 | 50.11M |
| June 30, 2025 | 70.51M |
| March 31, 2025 | 40.96M |
| December 31, 2024 | 36.31M |
| September 30, 2024 | 38.80M |
| June 30, 2024 | 30.52M |
| March 31, 2024 | 27.79M |
| December 31, 2023 | 27.42M |
| September 30, 2023 | 28.74M |
| June 30, 2023 | 22.73M |
| March 31, 2023 | 20.51M |
| December 31, 2022 | 22.22M |
| September 30, 2022 | 19.63M |
| June 30, 2022 | 21.68M |
| March 31, 2022 | 23.45M |
| December 31, 2021 | 24.55M |
| September 30, 2021 | 22.11M |
| June 30, 2021 | 24.18M |
| March 31, 2021 | 21.87M |
| December 31, 2020 | 27.72M |
| September 30, 2020 | 21.87M |
| June 30, 2020 | 18.75M |
| Date | Value |
|---|---|
| March 31, 2020 | 24.28M |
| December 31, 2019 | 26.78M |
| September 30, 2019 | 18.45M |
| June 30, 2019 | 20.38M |
| March 31, 2019 | 18.48M |
| December 31, 2018 | 21.06M |
| September 30, 2018 | 13.67M |
| June 30, 2018 | 19.20M |
| March 31, 2018 | 14.67M |
| December 31, 2017 | 16.37M |
| September 30, 2017 | 10.90M |
| June 30, 2017 | 13.53M |
| March 31, 2017 | 8.701M |
| December 31, 2016 | 11.14M |
| September 30, 2016 | 7.561M |
| June 30, 2016 | 11.58M |
| March 31, 2016 | 9.406M |
| December 31, 2015 | 8.214M |
| September 30, 2015 | 6.657M |
| June 30, 2015 | 9.262M |
| March 31, 2015 | 7.816M |
| December 31, 2014 | 9.749M |
| September 30, 2014 | 7.096M |
| June 30, 2014 | 8.290M |
| March 31, 2014 | 6.780M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Genmab A/S | 458.35M |
| Ascendis Pharma A/S | 85.39M |
| Bavarian Nordic A/S | 25.43M |
| Evaxion AS | 2.331M |
| Novo Nordisk A/S | 1.783B |